Fonadelpar

Drug Profile

Fonadelpar

Alternative Names: SJP 0035

Latest Information Update: 23 Mar 2017

Price : $50

At a glance

  • Originator Senju Pharmaceutical
  • Class Acetic acids; Benzoxazoles; Eye disorder therapies; Thiazoles
  • Mechanism of Action Peroxisome proliferator-activated receptor delta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Corneal disorders

Most Recent Events

  • 23 Mar 2017 Fonadelpar is still in phase II trials for Corneal disorders in USA (Ophthalmic)
  • 01 Sep 2016 Senju Pharmaceutical initiates a phase IIa trial for Corneal disorders in USA (Ophthalmic) (NCT02929823)
  • 25 May 2016 Chemical information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top